The proportion of patients with a ≥ 50% reduction in the monthly average number of headache days of at least moderate severity was significantly greater among fremanezumab quarterly and fremanezumab monthly groups compared with placebo, regardless of MO at baseline (with MO: quarterly 70/201 [34.8%, P < 0.0001], monthly 78/198 [39.4%, P < 0.0001] vs placebo 26/188 [13.8%]; without MO: quarterly 71/174 [40.8%, P = 0.0003], monthly 75/177 [42.4%, P < 0.0001] vs placebo 41/183 [22.4%, Fig. 2). The odds of achieving a ≥ 50% reduction (odds ratio [95% CI]) was greater with fremanezumab versus placebo in both patients with MO (quarterly 3.33 [2.01 to 5.52], monthly 4.08 [2.47 to 6.75]) and without MO (quarterly 2.37 [1.50 to 3.76], monthly 2.53 [1.60 to 4.00]).
Fig. 2 Proportion of patients with CM with ≥ 50% response (a) with MO and (b) without MO. A ≥ 50% response was defined as ≥ 50% reduction from baseline in the monthly average number of headache days of at least moderate severity over 12 weeks. CM, chronic migraine; MO, medication overuse